专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080287547A1 Glycine Transport Inhibitors 失效
标题翻译：甘氨酸运输抑制剂
公开(公告)号：US20080287547A1
公开(公告)日：2008-11-20
申请号：US11718333
申请日：2005-12-21
申请人： Daniel Marcus Bradley , Clive Leslie Branch , Wai Ngor Chan , Steven Coulton , Martin Leonard Gilpin , Andrew Jonathan Harris , Albert Andrzej Jaxa-Chamiec , Justine Yeun Quai Lai , Jacqueline Anne Macritchie , Howard Robert Marshall , David John Nash , Roderick Alan Porter , Simone Spada , Kevin Michael Thewlis , Simon Edward Ward
发明人： Daniel Marcus Bradley , Clive Leslie Branch , Wai Ngor Chan , Steven Coulton , Martin Leonard Gilpin , Andrew Jonathan Harris , Albert Andrzej Jaxa-Chamiec , Justine Yeun Quai Lai , Jacqueline Anne Macritchie , Howard Robert Marshall , David John Nash , Roderick Alan Porter , Simone Spada , Kevin Michael Thewlis , Simon Edward Ward
IPC分类号： A61K31/166 , A61P25/00 , C07C233/65 , A61P25/18
CPC分类号： C07C233/78 , C07C235/50 , C07C235/60 , C07C323/62 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D205/04 , C07D207/20 , C07D209/02 , C07D295/13 , C07D307/22
摘要： The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.
摘要翻译：本发明涉及式（I）化合物或其盐或溶剂化物，其用于制备用于治疗神经和神经精神障碍，特别是精神病，痴呆或注意力缺陷障碍的药物。本发明还包括制备这些化合物及其药物制剂的方法。

2. 发明申请

US20090270510A1 GLYCINE TRANSPORT INHIBITORS 审中-公开
标题翻译：甘氨酸运输抑制剂
公开(公告)号：US20090270510A1
公开(公告)日：2009-10-29
申请号：US11722213
申请日：2005-12-21
申请人： Daniel Marcus Bradley , Clive Leslie Branch , Wai Ngor Chan , Steven Coulton , Martin Leonard Gilpin , Andrew Jonathan Harris , Justine Yeun Quai Lai , Jacqueline Anne Macritchie , Howard Robert Marshall , David John Nash , Roderick Alan Porter , Simone Spada , Kevin Michael Thewlis , Simon Edward Ward
发明人： Daniel Marcus Bradley , Clive Leslie Branch , Wai Ngor Chan , Steven Coulton , Martin Leonard Gilpin , Andrew Jonathan Harris , Justine Yeun Quai Lai , Jacqueline Anne Macritchie , Howard Robert Marshall , David John Nash , Roderick Alan Porter , Simone Spada , Kevin Michael Thewlis , Simon Edward Ward
IPC分类号： A61K31/166 , C07C321/10 , C07C233/78 , C07C211/27
CPC分类号： C07C235/60 , C07C211/27 , C07C233/78 , C07C235/50 , C07C323/62
摘要： The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.
摘要翻译：本发明涉及式（I）化合物或其盐或溶剂合物，其用于制备用于治疗神经和神经精神障碍，特别是精神病，痴呆或注意力缺陷障碍的药物。本发明还包括制备这些化合物及其药物制剂的方法。

3. 发明申请

US20100216837A1 GLYCINE TRANSPORT INHIBITORS 审中-公开
标题翻译：甘氨酸运输抑制剂
公开(公告)号：US20100216837A1
公开(公告)日：2010-08-26
申请号：US11722210
申请日：2005-12-21
申请人： Andrea Bozzoli , Daniel Marcus Bradley , Steven Coulton , Martin Leonard Gilpin , Jacqueline Anne MacRitchie , Roderick Alan Porter , Kevin Michael Thewlis
发明人： Andrea Bozzoli , Daniel Marcus Bradley , Steven Coulton , Martin Leonard Gilpin , Jacqueline Anne MacRitchie , Roderick Alan Porter , Kevin Michael Thewlis
IPC分类号： A61K31/4709 , C07C231/06 , A61K31/166 , C07D215/50 , A61K31/47 , C07D333/06 , A61K31/381 , C07D207/04 , A61K31/40 , A61P25/00
CPC分类号： C07C211/36 , C07C211/29 , C07C229/34 , C07C233/78 , C07C271/22 , C07C2601/08 , C07D215/50 , C07D295/13 , C07D333/20 , C07D409/12
摘要： The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.
摘要翻译：本发明涉及式（I）化合物或其盐或溶剂合物，其用于制备用于治疗神经和神经精神障碍，特别是精神病，痴呆或注意力缺陷障碍的药物。本发明还包括制备这些化合物及其药物制剂的方法。

4. 发明申请

US20100137276A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE 审中-公开
标题翻译：潜在的AMPA受体的化合物及其在医学中的应用
公开(公告)号：US20100137276A1
公开(公告)日：2010-06-03
申请号：US12447294
申请日：2007-11-01
申请人： Daniel Marcus Bradley , Wai Ngor Chan , Kevin Michael Thewlis , Simon Eward
发明人： Daniel Marcus Bradley , Wai Ngor Chan , Kevin Michael Thewlis , Simon Eward
IPC分类号： A61K31/4162 , C07D487/04 , C07D471/04 , A61K31/437 , A61K31/397 , A61P25/18
CPC分类号： C07D491/052 , C07D471/04
摘要： Compounds of formula (I), and salts and solvates thereof are provided: Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.
摘要翻译：提供式（I）化合物及其盐和溶剂合物：制备方法，药物组合物及其作为药物的用途，例如治疗由谷氨酸受体功能的还原或不平衡介导的疾病或病症，如精神分裂症或认知障碍，也被披露。

5. 发明申请

US20080167351A1 Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine 失效
标题翻译：增加谷氨酸受体的化合物及其在医学中的应用
公开(公告)号：US20080167351A1
公开(公告)日：2008-07-10
申请号：US11816284
申请日：2006-02-13
申请人： Daniele Andreotti , Luca Arista , Francesca Cardullo , Simone Spada , Kevin Michael Thewlis , Simon Edward Ward
发明人： Daniele Andreotti , Luca Arista , Francesca Cardullo , Simone Spada , Kevin Michael Thewlis , Simon Edward Ward
IPC分类号： A61K31/44 , C07D213/02 , C07C311/01 , A61K31/18 , C07D333/02 , A61K31/381 , A61P25/18
CPC分类号： C07D277/64 , C07D213/42 , C07D213/61 , C07D213/65 , C07D317/58 , C07D333/20
摘要： This invention relates to potentiation of the glutamate receptor by novel compounds of formula (I): The invention also relates to the use of the derivatives in treating diseases and conditions mediated by potentiation of the glutamate receptor, compositions containing the derivatives and processes for their preparation.
摘要翻译：本发明涉及通过新的式（I）化合物增强谷氨酸受体：本发明还涉及该衍生物在治疗由谷氨酸受体增强介导的疾病和病症中的用途，含有衍生物的组合物及其制备方法。

6. 发明授权

US07790758B2 Compounds which potentiate glutamate receptor and uses thereof in medicine 失效
标题翻译：增强谷氨酸受体的药物及其在药物中的应用
公开(公告)号：US07790758B2
公开(公告)日：2010-09-07
申请号：US11816284
申请日：2006-02-13
申请人： Daniele Andreotti , Luca Arista , Francesca Cardullo , Simone Spada , Kevin Michael Thewlis , Simon Edward Ward
发明人： Daniele Andreotti , Luca Arista , Francesca Cardullo , Simone Spada , Kevin Michael Thewlis , Simon Edward Ward
IPC分类号： C07D333/20 , C07D317/58 , C07D277/64 , C07D213/61 , C07D213/42 , C07D213/647 , C07D213/64 , C07D213/65 , C07C311/08 , A61K31/4418 , A61K31/428 , A61K31/381 , A61K31/36 , A61K31/277 , A61K31/18
CPC分类号： C07D277/64 , C07D213/42 , C07D213/61 , C07D213/65 , C07D317/58 , C07D333/20
摘要： This invention relates to potentiation of the glutamate receptor by novel compounds of formula (I): The invention also relates to the use of the derivatives in treating diseases and conditions mediated by potentiation of the glutamate receptor, compositions containing the derivatives and processes for their preparation.
摘要翻译：本发明涉及通过新的式（I）化合物增强谷氨酸受体：本发明还涉及该衍生物在治疗由谷氨酸受体增强介导的疾病和病症中的用途，含有衍生物的组合物及其制备方法。

7. 发明授权

US07572819B2 Compounds which potentiate glutamate receptor and uses thereof in medicine 失效
标题翻译：增强谷氨酸受体的药物及其在药物中的应用
公开(公告)号：US07572819B2
公开(公告)日：2009-08-11
申请号：US11673044
申请日：2007-02-09
申请人： Daniel Marcus Bradley , Kevin Michael Thewlis , Simon Edward Ward
发明人： Daniel Marcus Bradley , Kevin Michael Thewlis , Simon Edward Ward
IPC分类号： A61K31/445 , C07D213/56
CPC分类号： C07D213/64 , C07D213/42 , C07D213/50 , C07D213/61 , C07D213/84 , C07D213/85 , C07D231/12 , C07D233/64 , C07D237/08 , C07D239/26 , C07D333/20
摘要： Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; each R4, which may be the same or different, is C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, monoC1-4alkylamino or diC1-4alkylamino; p is 0, 1 or 2; n is 1 or 2; R5 and R6, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consisting of C1-6alkyl, C1-6alkoxy, acetyl, halogen, haloC1-6alkyl, cyano, nitro, amino, monoC1-4alkylamino and diC1-4alkylamino. Methods of preparation of the compounds, and uses thereof in medicine, for example treatment of schizophrenia, are also disclosed.
摘要翻译：公开了式（I）化合物或其药学上可接受的盐，溶剂合物或前体药物：其中R 1是C 1-6烷基，卤代C 1-6烷基，C 2-6烯基，氨基，单C 1-4烷基氨基或二C 1-4烷基氨基; R 2和R 3可以相同或不同，为氢，卤素，C 1-6烷基，卤代C 1-6烷基，C 1-4烷氧基，卤代C 1-4烷氧基，氰基，氨基，单C 1-4烷基氨基或二C 1-4烷基氨基; 每个R 4可以相同或不同，为C 1-6烷基，卤素，C 1-6烷基，卤代C 1-6烷基，C 1-4烷氧基，卤代C 1-4烷氧基，氰基，硝基，氨基，单C 1-4烷基氨基或二C 1-4烷基氨基; p为0,1或2; n为1或2; R 5和R 6可以相同或不同，为氢，卤素，C 1-6烷基，卤代C 1-6烷基，C 1-4烷氧基，卤代C 1-4烷氧基，氰基，氨基，单C 1-4烷基氨基或二C 1-4烷基氨基; 并且Het是噻吩基，吡啶基，嘧啶基，哒嗪基，嘧啶基，吡嗪基，咪唑基，吡唑基，吡咯基，喹啉基，噻唑基或呋喃基，其各自可以被一个或多个独立地选自C 1-6烷基， 1-6烷氧基，乙酰基，卤素，卤代C 1-6烷基，氰基，硝基，氨基，单C 1-4烷基氨基和二C 1-4烷基氨基。还公开了化合物的制备方法及其在药物中的用途，例如精神分裂症的治疗。

8. 发明授权

US07618969B2 Compounds which potentiate glutamate receptor and uses thereof in medicine 失效
公开(公告)号：US07618969B2
公开(公告)日：2009-11-17
申请号：US11573370
申请日：2005-08-05
申请人： Daniel Marcus Bradley , Kevin Michael Thewlis , Simon Edward Ward
发明人： Daniel Marcus Bradley , Kevin Michael Thewlis , Simon Edward Ward
IPC分类号： A61K31/44 , C07D213/02
CPC分类号： C07D213/64 , C07D213/42 , C07D213/50 , C07D213/61 , C07D213/84 , C07D213/85 , C07D231/12 , C07D233/64 , C07D237/08 , C07D239/26 , C07D333/20
摘要： Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; each R4, which may be the same or different, is C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, monoC1-4alkylamino or diC1-4alkylamino; p is 0, 1 or 2; n is 1 or 2; R5 and R6, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consisting of C1-6alkyl, C1-6alkoxy, acetyl, halogen, haloC1-6alkyl, cyano, nitro, amino, monoC1-4alkylamino and diC1-4alkylamino. Methods of preparation of the compounds, and uses thereof in medicine, for example treatment of schizophrenia, are also disclosed.

9. 发明申请

US20080194648A1 COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE 失效
公开(公告)号：US20080194648A1
公开(公告)日：2008-08-14
申请号：US11673044
申请日：2007-02-09
申请人： Daniel Marcus Bradley , Kevin Michael Thewlis , Simon Edward Ward
发明人： Daniel Marcus Bradley , Kevin Michael Thewlis , Simon Edward Ward
IPC分类号： A61K31/44 , A61P25/18 , C07D211/84
CPC分类号： C07D213/64 , C07D213/42 , C07D213/50 , C07D213/61 , C07D213/84 , C07D213/85 , C07D231/12 , C07D233/64 , C07D237/08 , C07D239/26 , C07D333/20
摘要： Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; each R4, which may be the same or different, is C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, monoC1-4alkylamino or diC1-4alkylamino; p is 0, 1 or 2; n is 1 or 2; R5 and R6, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consisting of C1-6alkyl, C1-6alkoxy, acetyl, halogen, haloC1-6alkyl, cyano, nitro, amino, monoC1-4alkylamino and diC1-4alkylamino. Methods of preparation of the compounds, and uses thereof in medicine, for example treatment of schizophrenia, are also disclosed.

10. 发明授权

US07741351B2 Compounds which potentiate glutamate receptor and uses thereof in medicine 失效
标题翻译：增强谷氨酸受体的药物及其在药物中的应用
公开(公告)号：US07741351B2
公开(公告)日：2010-06-22
申请号：US11573368
申请日：2005-08-05
申请人： Kevin Michael Thewlis , Simon Edward Ward
发明人： Kevin Michael Thewlis , Simon Edward Ward
IPC分类号： A61K31/425 , A61K31/40 , A61K31/275 , A61K31/17
CPC分类号： C07D207/27 , C07C311/07 , C07C311/08 , C07C311/37 , C07C317/28 , C07C2602/08 , C07D275/02
摘要： This case discloses compounds of formula (I) wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano or amino; each R4, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; p is 0, 1 or 2; each R5, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; q is 0, 1 or 2; R6 is —NR6aSO2R6b, —NR6aC(═O)R6b, —NR6a(C═O)N(R6c)2, —(C═O)R6d, —CH2NR6aSO2R6b, —CH2NR6aC(═O)R6b, CH2NR6a(C═O)N(R6c)2 or —CH2(C═O)R6d; where R6a and each R6c, which may be the same or different, is hydrogen or C1-6alkyl; R6b and R6d are C1-6alkyl or haloC1-6alkyl; or R6a and R6b, or R6a and R6c, together with the interconnecting atoms, may form a 5- or 6-membered ring; n is 1 or 2; and R7 and R8, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano or amino. It also discloses methods for preparing the compounds and their use in therapy such as treating schizophrenia.
摘要翻译：本例公开了式（I）的化合物，其中R 1是C 1-6烷基，卤代C 1-6烷基，C 2-6烯基，氨基，单C 1-4烷基氨基或二C 1-4烷基氨基; R 2和R 3可以相同或不同，是氢，卤素，C 1-6烷基，卤代C 1-6烷基，C 1-4烷氧基，卤代C 1-4烷氧基，氰基或氨基; 每个R 4可以相同或不同，为C 1-6烷基，卤素，卤代C 1-6烷基，C 1-4烷氧基，卤代C 1-4烷氧基，氰基，硝基或氨基; p为0,1或2; 每个R 5可以相同或不同，是C 1-6烷基，卤素，卤代C 1-6烷基，C 1-4烷氧基，卤代C 1-4烷氧基，氰基，硝基或氨基; q是0,1或2; R6是-NR6aSO2R6b，-NR6aC（= O）R6b，-NR6a（C = O）N（R6c）2， - （C = O）R6d，-CH2NR6aSO2R6b，-CH2NR6aC（= O）R6b，CH2NR6a ）N（R6c）2或-CH2（C = O）R6d; 其中R 6a和R 6c可以相同或不同，是氢或C 1-6烷基; R6b和R6d是C1-6烷基或卤代C 1-6烷基; 或R6a和R6b或R6a和R6c与互连原子一起可以形成5-或6-元环; n为1或2; 和可以相同或不同的R 7和R 8是氢，卤素，C 1-6烷基，卤代C 1-6烷基，C 1-4烷氧基，卤代C 1-4烷氧基，氰基或氨基。它还公开了制备化合物的方法及其在诸如治疗精神分裂症的治疗中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式